Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 9:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 172 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Macular Degeneration
Interventions
bevasiranib, ranibizumab
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
50 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
55
States / cities
Phoenix, Arizona • Tucson, Arizona • Fresno, California + 47 more
Conditions
Macular Edema, Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusion
Interventions
MHU650
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Huntington Beach, California • Honolulu, Hawaii • Hagerstown, Maryland + 2 more
Conditions
Macular Degeneration, Wet Macular Degeneration
Interventions
Intravitreal aflibercept injection
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
50 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
La Jolla, California
Conditions
Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
Interventions
Tiespectus, Aflibercept
Drug
Lead sponsor
EyeBiotech Ltd.
Industry
Eligibility
50 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
9
States / cities
Mountain View, California • Lemont, Illinois • Hagerstown, Maryland + 6 more
Withdrawn No phase listed Observational Accepts healthy volunteers

Study Evaluating Retinal Health Monitoring System Thickness Module

NCT04428242
Conditions
Macular Edema, Macular Degeneration
Interventions
RHMS-RTM, SD-OCT
Device · Diagnostic Test
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Sacramento, California
Conditions
Neovascular (Wet) Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, Diabetic Retinopathy
Interventions
SCD411 0.05mL (2mg)
Drug
Lead sponsor
Sam Chun Dang Pharm. Co. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
4
States / cities
Stuart, Florida • Winter Haven, Florida • Lemont, Illinois + 1 more
Conditions
Macular Degeneration
Interventions
AdGVPEDF.11D
Drug
Lead sponsor
GenVec
Industry
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
Beverly Hills, California • Los Angeles, California • Boynton Beach, Florida + 5 more
Conditions
Age Related Macular Degeneration, Choroidal Neovascular Membrane, Subfoveal Neovascular Age-Related Macular Degeneration, Macular Degeneration, Wet Age-Related Macular Degeneration
Interventions
Ranibizumab
Drug
Lead sponsor
David M. Brown, M.D.
Other
Eligibility
50 Years and older
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
2
States / cities
Houston, Texas • The Woodlands, Texas
Recruiting No phase listed Observational Accepts healthy volunteers

OCT Angiography in Wet AMD

NCT02253030
Conditions
Neovascular (Wet) Age-related Macular Degeneration (AMD)
Interventions
Optical Coherence Tomography
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
50 Years to 100 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
PDS Implant filled with 100 mg/mL Ranibizumab, Intravitreal Injections of 10 mg/mL Ranibizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
77
States / cities
Mesa, Arizona • Phoenix, Arizona • Bakersfield, California + 66 more
Conditions
Macular Degeneration, Choroidal Neovascularization
Interventions
episcleral brachytherapy
Radiation
Lead sponsor
Salutaris Medical Devices, Inc.
Industry
Eligibility
50 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
2
States / cities
‘Aiea, Hawaii • Oak Forest, Illinois
Conditions
Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration
Interventions
Faricimab, OLN324
Drug
Lead sponsor
Ollin Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
29
States / cities
Phoenix, Arizona • Glendale, California • Pasadena, California + 26 more
Conditions
Exudative Age-Related Macular Degeneration
Interventions
ranibizumab and dexamethasone, Ranibizumab
Drug
Lead sponsor
Subhransu K. Ray, M.D., Ph.D.
Other
Eligibility
50 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Walnut Creek, California
Conditions
Age-Related Macular Degeneration, Macular Degeneration, Wet Macular Degeneration, Retinal Degeneration, Retinal Diseases, Eye Diseases
Interventions
brolucuzumab 6 mg IVT
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
2
States / cities
Phoenix, Arizona • Abilene, Texas
Conditions
Exudative Macular Degeneration
Interventions
TRIPLE COMBINATION THERAPY
Procedure
Lead sponsor
The Retina Center of St. Louis County, PC
Other
Eligibility
50 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Exudative Age-related Macular Degeneration
Interventions
Aflibercept
Drug
Lead sponsor
Palmetto Retina Center, LLC
Other
Eligibility
Not listed
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
6
States / cities
Augusta, Georgia • Lincoln, Nebraska • West Columbia, South Carolina + 3 more
Conditions
Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Interventions
Ixo-vec, Aflibercept
Genetic · Drug
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
50 Years and older
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
65
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 53 more
Conditions
Macular Degeneration
Interventions
Microplasmin, Placebo control
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Neovascular Age-related Macular Degeneration
Interventions
CLS-AX, Aflibercept
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
32
States / cities
Phoenix, Arizona • Bakersfield, California • Fullerton, California + 28 more
Conditions
Wet Macular Degeneration, Wet Age-related Macular Degeneration
Interventions
Ziv-Aflibercept 25 MG/ML [Zaltrap], Ranibizumab
Drug
Lead sponsor
Kapil Kapoor
Other
Eligibility
50 Years to 99 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Virginia Beach, Virginia
Conditions
Age Related Macular Degeneration
Interventions
HLX04-O, ranibizumab
Drug
Lead sponsor
Shanghai Henlius Biotech
Industry
Eligibility
50 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
42
States / cities
Gilbert, Arizona • Phoenix, Arizona • Fullerton, California + 34 more
Conditions
Macular Degeneration
Interventions
MSI-1256F (Squalamine Lactate)
Drug
Lead sponsor
Genaera Corporation
Industry
Eligibility
50 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Plymouth Meeting, Pennsylvania
Conditions
Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease, Optic Neuropathy, Nonarteritic Ischemic Optic Neuropathy, Optic Atrophy, Optic Nerve Disease, Glaucoma, Leber Hereditary Optic Neuropathy, Blindness, Vision Loss Night, Vision Loss Partial, Vision, Low, Retinopathy, Maculopathy, Macular Degeneration, Retina Atrophy
Interventions
Arm 1
Procedure
Lead sponsor
MD Stem Cells
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
2
States / cities
Westport, Connecticut • Coral Springs, Florida
Conditions
Macular Degeneration
Interventions
Retisert Implant
Drug
Lead sponsor
Control Delivery Systems
Industry
Eligibility
55 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Watertown, Massachusetts